Export Lists for Human Food: Request for Information; Extension of Comment Period, 105059-105060 [2024-30784]

Download as PDF Federal Register / Vol. 89, No. 247 / Thursday, December 26, 2024 / Notices records about subscribers, which are retrieved by the subscriber’s name or email address. POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS: ddrumheller on DSK120RN23PROD with NOTICES1 Records about individuals who serve as members of Federal advisory committees and subgroups are retained and disposed of in accordance with NARA General Records Schedule (GRS) 6.2, Items 010, 040, and 050: • Item 010 Substantive Committee Records requires substantive records related to committee and subgroup membership to be accessioned to the National Archives for permanent retention when the records are 15 years old or older or upon termination of the committee, whichever is sooner. • Item 040 Committee Accountability Records (note that this item excludes forms filed under the Ethics in Government Act, and such forms are not covered by this SORN) authorizes accountability records (such as records about members’ financial disclosures and conflicts of interest, and records documenting travel and other payments to or for committee members) to be destroyed when 6 years old unless longer retention is required for business use. • Item 050 Non-substantive Committee Records authorizes records of an administrative nature, such as those documenting members’ and prospective members’ credentials, to be destroyed when superseded, obsolete, or no longer needed, or upon termination of the committee, whichever is sooner. Records about prospective members of Federal advisory committees are retained and disposed of in accordance with GRS 6.2, Item 050 (see above). Records about guest speakers are disposed of in accordance with GRS 6.2, Item 040 (see above). Records about meeting registrants and subscribers are retained and disposed of in accordance with GRS 6.5, Item 020, which authorizes sign-up forms and distribution lists for distributing information such as publications and data produced by the agency to be deleted when superseded or obsolete or when the customer requests the agency to remove the records. ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS: Records are protected from unauthorized access through appropriate administrative, physical, and technical safeguards. Safeguards conform to the HHS Information Security and Privacy Program, https:// www.hhs.gov/ocio/securityprivacy/. The safeguards include protecting the VerDate Sep<11>2014 19:37 Dec 23, 2024 Jkt 265001 facilities where records are stored or accessed with security guards, badges, and cameras; securing hard-copy records in locked file cabinets, file rooms or offices during off-duty hours; limiting access to electronic databases to authorized users based on roles, the principle of least privilege, and either two-factor authentication or user ID and password; using a secured operating system protected by encryption, firewalls, and intrusion detection systems; encrypting data transmissions and records stored on removable media; using secure destruction methods prescribed in National Institute of Standards and Technology Special Publication 800–88 to dispose of eligible records; and training personnel in Privacy Act and information security requirements. An individual seeking access to records about him or her in this system of records must submit a written access request to the relevant System Manager, at the address indicated in the ‘‘System Manager(s)’’ section, above, in accordance with the Department’s Privacy Act implementation regulations in 45 CFR. The request must contain the individual’s full name and address, and, for identity verification purposes, signature, and date and place of birth. In addition, to verify the individual’s identity, the individual must provide either a notarized request or a written certification that the individual is who he or she claims to be and understands that the knowing and willful request for acquisition of a record pertaining to an individual under false pretenses is a criminal offense under the Privacy Act, subject to a fine of up to $5,000. CONTESTING RECORD PROCEDURES: An individual seeking to amend a record about him or her in this system of records must submit a written amendment request to the relevant System Manager, at the address indicated in the ‘‘System Manager(s)’’ section, above, in accordance with the Department’s Privacy Act implementation regulations in 45 CFR. The request must contain the same information required for an access request, and must reasonably identify the record, specify the information contested, state the corrective action sought, provide the reasons for the amendment, and include any supporting justification or documentation. The individual must verify his or her identity in the same manner required for an access request. The right to contest records is limited to information that is factually inaccurate, Frm 00095 Fmt 4703 Sfmt 4703 incomplete, irrelevant, or untimely (obsolete). NOTIFICATION PROCEDURES: An individual who wishes to know if this system of records contains records about him or her must submit a written notification request to the relevant System Manager at the address indicated in the ‘‘System Manager(s)’’ section, above, in accordance with the Department’s Privacy Act implementation regulations in 45 CFR. The request must contain the same information required for an access request, and the individual must verify his or her identity in the same manner required for an access request. EXEMPTIONS PROMULGATED FOR THE SYSTEM: None. HISTORY: RECORD ACCESS PROCEDURES: PO 00000 105059 47 FR 45514 (October 13, 1982); 59 FR 55845 (November 9, 1994); 83 FR 6591 (February 14, 2018). Dated: December 13, 2024. P. Ritu Nalubola, Associate Commissioner for Policy. [FR Doc. 2024–30782 Filed 12–23–24; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2024–N–4776] Export Lists for Human Food: Request for Information; Extension of Comment Period AGENCY: Food and Drug Administration, HHS. Notice; request for information; extension of comment period. ACTION: The Food and Drug Administration (FDA or we) is extending the comment period for the request for information, published in the Federal Register of November 8, 2024. In that notice, FDA invited comment relating to the listing requirements of other countries and FDA’s approach to facilitating U.S. industry compliance with these requirements through the issuance of export certification for human food products provided in the form of lists (export lists). We are extending the comment period to allow interested persons additional time to submit comments on FDA’s approach. DATES: FDA is extending the comment period announced in the notice for request for information published November 8, 2024 (89 FR 88785). SUMMARY: E:\FR\FM\26DEN1.SGM 26DEN1 105060 Federal Register / Vol. 89, No. 247 / Thursday, December 26, 2024 / Notices Electronic or written comments must be submitted by February 21, 2025. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https:// www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of February 21, 2025. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date. ddrumheller on DSK120RN23PROD with NOTICES1 Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2024–N–4776 for ‘‘Export Lists for Human Food: Request for Information.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for VerDate Sep<11>2014 19:37 Dec 23, 2024 Jkt 265001 those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ We will review this copy, including the claimed confidential information, in our consideration of comments. The second copy, which will have the claimed confidential information redacted/ blacked out, will be available for public viewing and posted on https:// www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500. FOR FURTHER INFORMATION CONTACT: Lauren Ferguson Baham, Office of Policy, Regulations, and Information, Human Foods Program, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240–402–2371. SUPPLEMENTARY INFORMATION: In the Federal Register of November 8, 2024, we published a notice announcing a request for information. The notice explained our export certification for human foods and that FDA is considering charging firms fees for our export list services to offset our costs. The notice also explained that, as of PO 00000 Frm 00096 Fmt 4703 Sfmt 9990 August 2024, we provide certification in the form of export lists that cover 19 categories of products for six destinations: Chile, China, the European Union, Saudi Arabia, Taiwan, and the United Kingdom. Further, the notice explained that, to better inform the continuing development of our export list program for human foods, we invited public comment on the following: • There are many different types of establishment listing and certification procedures for establishments that produce human food products. Please share your experience with other countries’ establishment listing, certification, and registration requirements. • FDA requires those on export lists to reapply regularly if they wish to remain listed. Do reapplicants experience any challenges with the renewal process? If you have experienced challenges, how were those challenges resolved? • For those included on export lists, please describe any challenges you have experienced with exporting human food products included on the export lists. • FDA is authorized to collect up to $175 per certification for each company and its human food products that FDA certifies through inclusion on an export list. For those that would be charged a fee, do you have any specific suggestions about how FDA should approach the implementation of fees? Please provide details relating to any suggestions you might have (89 FR 88785). The docket for public comments was scheduled to close January 7, 2025. We have received several requests to extend the comment period. In general, the requests explain that FDA’s consideration to charge fees for its export list services to offset costs is a significant change from current Agency practice that will take firms time to fully evaluate the impacts of the proposed changes and to provide substantive comment that details firms’ experiences and challenges with export lists. The requests also note that the comment period overlaps with the holiday season. We have considered the requests and are extending the comment period until February 21, 2025. We believe that the extension will allow adequate time for interested persons to submit comments. Dated: December 18, 2024. P. Ritu Nalubola, Associate Commissioner for Policy. [FR Doc. 2024–30784 Filed 12–23–24; 8:45 am] BILLING CODE 4164–01–P E:\FR\FM\26DEN1.SGM 26DEN1

Agencies

[Federal Register Volume 89, Number 247 (Thursday, December 26, 2024)]
[Notices]
[Pages 105059-105060]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30784]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2024-N-4776]


Export Lists for Human Food: Request for Information; Extension 
of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for information; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or we) is extending the 
comment period for the request for information, published in the 
Federal Register of November 8, 2024. In that notice, FDA invited 
comment relating to the listing requirements of other countries and 
FDA's approach to facilitating U.S. industry compliance with these 
requirements through the issuance of export certification for human 
food products provided in the form of lists (export lists). We are 
extending the comment period to allow interested persons additional 
time to submit comments on FDA's approach.

DATES: FDA is extending the comment period announced in the notice for 
request for information published November 8, 2024 (89 FR 88785).

[[Page 105060]]

Electronic or written comments must be submitted by February 21, 2025.

ADDRESSES: You may submit comments as follows. Please note that late, 
untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 
11:59 p.m. Eastern Time at the end of February 21, 2025. Comments 
received by mail/hand delivery/courier (for written/paper submissions) 
will be considered timely if they are received on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2024-N-4776 for ``Export Lists for Human Food: Request for 
Information.'' Received comments, those filed in a timely manner (see 
ADDRESSES), will be placed in the docket and, except for those 
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. 
and 4 p.m., Monday through Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We will review 
this copy, including the claimed confidential information, in our 
consideration of comments. The second copy, which will have the claimed 
confidential information redacted/blacked out, will be available for 
public viewing and posted on https://www.regulations.gov. Submit both 
copies to the Dockets Management Staff. If you do not wish your name 
and contact information to be made publicly available, you can provide 
this information on the cover sheet and not in the body of your 
comments and you must identify this information as ``confidential.'' 
Any information marked as ``confidential'' will not be disclosed except 
in accordance with 21 CFR 10.20 and other applicable disclosure law. 
For more information about FDA's posting of comments to public dockets, 
see 80 FR 56469, September 18, 2015, or access the information at: 
https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Lauren Ferguson Baham, Office of 
Policy, Regulations, and Information, Human Foods Program, Food and 
Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-
2371.

SUPPLEMENTARY INFORMATION: In the Federal Register of November 8, 2024, 
we published a notice announcing a request for information. The notice 
explained our export certification for human foods and that FDA is 
considering charging firms fees for our export list services to offset 
our costs. The notice also explained that, as of August 2024, we 
provide certification in the form of export lists that cover 19 
categories of products for six destinations: Chile, China, the European 
Union, Saudi Arabia, Taiwan, and the United Kingdom. Further, the 
notice explained that, to better inform the continuing development of 
our export list program for human foods, we invited public comment on 
the following:
     There are many different types of establishment listing 
and certification procedures for establishments that produce human food 
products. Please share your experience with other countries' 
establishment listing, certification, and registration requirements.
     FDA requires those on export lists to reapply regularly if 
they wish to remain listed. Do reapplicants experience any challenges 
with the renewal process? If you have experienced challenges, how were 
those challenges resolved?
     For those included on export lists, please describe any 
challenges you have experienced with exporting human food products 
included on the export lists.
     FDA is authorized to collect up to $175 per certification 
for each company and its human food products that FDA certifies through 
inclusion on an export list. For those that would be charged a fee, do 
you have any specific suggestions about how FDA should approach the 
implementation of fees? Please provide details relating to any 
suggestions you might have (89 FR 88785).
    The docket for public comments was scheduled to close January 7, 
2025.
    We have received several requests to extend the comment period. In 
general, the requests explain that FDA's consideration to charge fees 
for its export list services to offset costs is a significant change 
from current Agency practice that will take firms time to fully 
evaluate the impacts of the proposed changes and to provide substantive 
comment that details firms' experiences and challenges with export 
lists. The requests also note that the comment period overlaps with the 
holiday season.
    We have considered the requests and are extending the comment 
period until February 21, 2025. We believe that the extension will 
allow adequate time for interested persons to submit comments.

    Dated: December 18, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2024-30784 Filed 12-23-24; 8:45 am]
BILLING CODE 4164-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.